Fibrocell’s Gene Therapy for Localized Scleroderma Designated an Orphan Drug by FDA
News, Scleroderma
Fibrocell Science, Inc., recently announced that the U.S. Food and Drug Administration (FDA) has designated FCX-013 an orphan drug for the potential treatment of localized scleroderma, a chronic autoimmune disease in which the ... Read more